We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting (SBIRT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01300806
First Posted: February 23, 2011
Last Update Posted: May 22, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of California, San Francisco
  Purpose
The goal of this research is to assess the impact of the "screening, brief intervention, and referral to treatment" (SBIRT) intervention strategy for harmful substance use among HIV-positive people.

Condition
Substance Use

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • reduced substance use among HIV-positive people [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • technological innovation to improve the quality of medical care [ Time Frame: 6 months ]

Enrollment: 210
Study Start Date: July 2010
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
myHERO SBIRT
clinician administered SBIRT

Detailed Description:

The specific aims of the study are:

  1. To assess the feasibility of conducting SBIRT using (1) a patient self-administered intervention embedded in a web-based Personal Health Record (PHR) compared to (2) a provider-administered SBIRT intervention guided by the Electronic Medical Record (EMR) during clinic appointments.
  2. To examine the acceptability of web-based PHRs to conduct and communicate SBIRT compared to EMR-activated SBIRT conducted by clinic staff, from the perspective of the patient and the provider.
  3. To assess the impact of SBIRT on risky drug and alcohol use in an HIV/AIDS population and subsequent effects on sexual risk behaviors and antiretroviral therapy (ART) adherence.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
primary care clinic patients
Criteria

Inclusion Criteria:

  • 18 years of age
  • confirmed prior HIV+ serostatus
  • ability to provide informed consent to be a participant over a 6 month period
  • English or Spanish speaking

Exclusion Criteria:

Inability to answer questions with interviewer assistance. Not receiving primary care in clinic.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01300806


Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Carol Dawson Rose, PhD University of California, San Francisco
  More Information

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01300806     History of Changes
Other Study ID Numbers: 09035355
First Submitted: February 17, 2010
First Posted: February 23, 2011
Last Update Posted: May 22, 2013
Last Verified: May 2013

Keywords provided by University of California, San Francisco:
HIV
harmful substance use